Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure

Acute-on-chronic liver failure (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality. Systemic inflammation and susceptibility to infection are characteristic pathophysiological features. Prostaglandin E2 (PGE2) could subdue systemic inflammation and alleviate liver injury in mice model. However, there are no studies evaluating PGE2 as a predictor of early mortality.This study is designed to investigate whether plasma PGE2 and its receptors are associated with development of MOF and predict short-term mortality in patients with acute-on-chronic liver failure. By the way, we will also measure several other potential predictive factors (C-reactive protein,severe hyponatremia, Second infections,Diabetes mellitus,High density lipoprotein,interleukin-10,serum bile acids,ferritin,the neutrophil to lymphocyte ratio,soluable urokinase plasminogen activator receptor,vWF-Ag levels and FVIII-to-PC ratios).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute-On-Chronic Liver Failure Cirrhosis and Chronic Liver Disease Digestive System Diseases Fibrosis Hepatic Insufficiency Liver Diseases Liver Failure Liver Failure, Acute Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of acute-on-chronic liver failure according to Asian-Pacific Association for the Study of the Liver (APASL) diagnostic criteria

Exclusion criteria

Hepatocellular carcinoma(HCC)
Portal vein thrombosis
Pregnancy
Human immunodeficiency virus (HIV)
Patients who had received immunomodulator,or cytotoxic/immunosuppressive therapy within at least the preceding 12 months

Treatment and study plan

plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.

Diagnostic Test

Primary outcomes

all cause mortality

Time frame: 90 days
incidence of multiorgan failure

Time frame: 90 days
all cause mortality

Time frame: 30 days

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Zhejiang University

Other

Registry information

Official study title

A Study on Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure

Acronym: PGE2

Important dates

Study start: 2016
Primary completion: 2017
Study completion: 2018
First posted: Nov 16, 2016
Registry last updated: Jun 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed